Evidence map›Paper›PMID 30537127›Full record

ArticleJournal of cellular physiology2019

Activating Mas receptor protects human pulmonary microvascular endothelial cells against LPS-induced apoptosis via the NF-kB p65/P53 feedback pathways.

Weifeng Huang, Yongmei Cao, Yujing Liu, Feng Ping, Jiawei Shang, Zhongwei Zhang, Yingchuan Li

Abstract read
In one paragraph

Article in Journal of cellular physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. The role of SARS-CoV-2-mediated NF-κB activation in COVID-19 patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Review
  2. Advances in Biomarkers for Diagnosis and Treatment of ARDS.Diagnostics (Basel, Switzerland) · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Does COVID19 activates previous chronic pain? A case series.Annals of medicine and surgery (2012) · 2021
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Weifeng HuangDepartment of Critical Care Medicine, Shanghai Jiaotong University affiliated to The Sixth People's Hospital, Shanghai, China.
Yongmei CaoDepartment of Critical Care Medicine, Shanghai Jiaotong University affiliated to The Sixth People's Hospital, Shanghai, China.ORCID 0000-0002-8261-3008
Yujing LiuDepartment of Critical Care Medicine, Shanghai Jiaotong University affiliated to The Sixth People's Hospital, Shanghai, China.
Feng PingDepartment of Critical Care Medicine, Shanghai Jiaotong University affiliated to The Sixth People's Hospital, Shanghai, China.
Jiawei ShangDepartment of Critical Care Medicine, Shanghai Jiaotong University affiliated to The Sixth People's Hospital, Shanghai, China.
Zhongwei ZhangDepartment of Critical Care Medicine, Shanghai Jiaotong University affiliated to The Sixth People's Hospital, Shanghai, China.
Yingchuan LiDepartment of Critical Care Medicine, Shanghai Jiaotong University affiliated to The Sixth People's Hospital, Shanghai, China.
Shanghai Sixth People's Hospital · CNZero to Three · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The balance between Ang II/AT1R and Ang-(1-7)/Mas plays a pivotal role in the development of lipopolysaccharides (LPS)-induced acute respiratory distress syndrome. However, the mechanisms underlying the balancing process still remain unclear. Here we investigated the roles of nuclear factor (NF)-κB and p53 in regulating AT1R and Mas expression. The results demonstrated that Ang II pretreatment resulted in downregulation of Mas and upregulation of AT1R, phosphorylated p65, and apoptosis in LPS-treated Human pulmonary microvascular endothelial cells (HPMVECs), but had no effect on p53 expression. Lentiviral vector-mediated P65 knockdown, but not a P53 knockdown, reversed all these effects of Ang II. On the other hand, Ang-(1-7) pretreatment lead to an increased in Mas expression and a decrease in AT1R, p53, and phosphorylated p65 expressions with suppressed apoptosis in LPS-treated cells. P65 knockdown promoted the protein expression of both AT1R and Mas while inhibiting p53 expression. P53 knockdown, but not a p65 knockdown, reversed all these effects of Ang-(1-7). Interestingly, p65 overexpression upregulated p53 and AT1R but downregulated Mas. P53 knockdown activated p65. These results suggest that there is a two-way feedback regulation between AT1R and Mas receptor via the NF-kB p65/P53 pathway, which may play a key role in LPS-induced HPMVECs apoptosis.

Indexed as

Angiotensin IIApoptosisEndothelial CellsHumansLipopolysaccharidesLungNF-kappa BProtective AgentsSignal TransductionUp-RegulationAngiotensin IILipopolysaccharidesNF-kappa BProtective AgentsapoptosisMas receptornuclear factor (NF)-kB p65P53 pathwaypulmonary microvascular endothelial cells

Identifiers

PMID30537127
PMCPMC13483338
OpenAlexW2904239912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.